Novartis preps Zykadia for a frontline NSCLC pitch, but faces a tough rival in Roche; J&J, GSK hustle RA drug sirukumab to the FDA
Novartis plans to hustle to regulators with new late-stage data on their cancer drug Zykadia (certinib), looking for an approval to move up to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
